Cherry Biotech

Founded in 2014 by Jérémy Cramer and Guilhem Velve-Casquillas, Cherry Biotech is a biomedical technology company that has developed out of the deeptech hardware space in France. The company is focused on reducing the reliance on animal testing in the pharmaceutical and biotech industries.

Cherry Biotech provides an advanced organ-on-chip platform, CUBIX, designed for drug discovery and personalized medicine. This technology enables pharmaceutical companies, biotech firms, and healthcare providers to create immunocompetent, vascularized human organ models and tumor microenvironments. The primary business model revolves around the sale of these CUBIX platforms and associated consumables to research and development labs.

The core of the offering is its patented Organ on Well technology, which transforms standard 2D multi-well plates into 3D cell culture environments. This system can sustain 3D cell cultures, spheroids, and organoids for extended periods, closely mimicking human physiology and pathophysiology. This allows for more accurate and predictive testing of drug candidates before they enter clinical trials, addressing the ethical and regulatory shifts away from animal experimentation while integrating with existing laboratory workflows.

Keywords: Organ-on-chip, 3D cell culture, drug discovery, personalized medicine, animal testing alternatives, in-vitro models, organoids, CUBIX, biomedical technology, preclinical trials.